European Society for Medical Oncology (ESMO) Virtual Congress 2020

Nivolumab does not improve overall survival (OS) in patients with platinum-resistant ovarian cancer when compared with standard second- and subsequent-line chemotherapy, according to the results of the phase III NINJA trial presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Precision therapy for prostate cancer (PC) is becoming reality, with recent studies demonstrating efficacy of this approach in patients with metastatic castration-resistant PC (mCRPC) with certain DNA damage repair (DDR) alterations or PTEN loss.

A combined regimen of apatinib plus gefitinib as first-line treatment improves progression-free survival (PFS) vs placebo plus gefitinib in patients with advanced EGFR-mutant (EGFRm) non-squamous non-small-cell lung cancer (NSCLC), results of the phase III ACTIVE study have shown.

The combination of nivolumab and cabozantinib in the first-line setting conferred greater survival outcomes and responses compared with sunitinib in patients with clear cell advanced renal cell carcinoma (RCC), results of the phase III CheckMate 9ER trial showed.

Adding abemaciclib to adjuvant endocrine therapy (ET) resulted in improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in women with hormone receptor (HR)+, HER2-negative, node-positive early breast cancer at high risk of recurrence, results of the phase III monarchE* trial showed.

Durvalumab with or without tremelimumab in the first-line setting does not improve overall survival (OS) over standard-of-care (SoC) chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma, according to the phase III DANUBE trial.